- Home
- SONM vs KZIA Comparison
SONM vs KZIA Comparison
Compare SONM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONM
- KZIA
- Stock Information
- Founded
- SONM 1999
- KZIA 1994
- Country
- SONM United States
- KZIA Australia
- Employees
- SONM N/A
- KZIA N/A
- Industry
- SONM Telecommunications Equipment
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SONM Telecommunications
- KZIA Health Care
- Exchange
- SONM Nasdaq
- KZIA Nasdaq
- Market Cap
- SONM 10.2M
- KZIA 5.1M
- IPO Year
- SONM 2019
- KZIA 1999
- Fundamental
- Price
- SONM $1.35
- KZIA $6.28
- Analyst Decision
- SONM
- KZIA Strong Buy
- Analyst Count
- SONM 0
- KZIA 2
- Target Price
- SONM N/A
- KZIA $57.50
- AVG Volume (30 Days)
- SONM 11.7M
- KZIA 2.6M
- Earning Date
- SONM 08-08-2025
- KZIA 07-07-2025
- Dividend Yield
- SONM N/A
- KZIA N/A
- EPS Growth
- SONM N/A
- KZIA N/A
- EPS
- SONM N/A
- KZIA N/A
- Revenue
- SONM $58,243,000.00
- KZIA $1,549,158.00
- Revenue This Year
- SONM $127.68
- KZIA N/A
- Revenue Next Year
- SONM N/A
- KZIA N/A
- P/E Ratio
- SONM N/A
- KZIA N/A
- Revenue Growth
- SONM N/A
- KZIA 248983.08
- 52 Week Low
- SONM $0.85
- KZIA $2.86
- 52 Week High
- SONM $10.50
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- SONM 59.58
- KZIA 50.96
- Support Level
- SONM $0.97
- KZIA $5.83
- Resistance Level
- SONM $2.08
- KZIA $9.60
- Average True Range (ATR)
- SONM 0.30
- KZIA 1.19
- MACD
- SONM 0.06
- KZIA -0.29
- Stochastic Oscillator
- SONM 58.23
- KZIA 18.39
About SONM Sonim Technologies Inc.
Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.